In October 2025, the FDA approved Rybelsus (oral semaglutide, developed by Novo Nordisk) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk
Appetite suppression : These medications act on the brain to reduce hunger and cravings
RedVive Red Light Therapy If you suffer from chronic foot pain or a frustrating foot condition without relief, you may find new hope with a treatment called RedVive red light therapy
It may help contextualize your individual risk profile and support a more informed conversation with your provider about personalized monitoring
Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, et al
Published in North and South America by CRC Press LLC, Corporate Blvd, NW Boca Raton FL 33431, USA